Celladon Corp (CLDN) 21.67 $CLDN
Celladon reports Q4 results
Seeking Alpha - at Seeking Alpha - 1 hr 10 mins ago
CLDN: 21.67 (+0.58)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:11AM CDT
BDSI: 10.51 (-3.38), CRMD: 8.70 (+0.56), NCFT: 25.67 (+2.77), LEJU: 8.47 (+0.56), CTRX: 59.83 (+11.51), ZIOP: 11.61 (+0.17), ADXS: 13.44 (+0.29), CNAT: 7.53 (-0.22), XON: 46.30 (+3.30), BBEP: 5.55 (-0.35), ADMP: 3.83 (-1.56), CLDN: 21.67 (+0.58), ASPX: 100.36 (+29.45), HPTX: 45.98 (+3.24), GENE: 4.94 (+1.24), SYN: 2.29 (-0.03), ICEL: 16.42 (+8.48), HZNP: 25.78 (+3.97), OHRP: 2.81 (+0.07), SFUN: 6.35 (+0.39), CNET: 1.66 (+0.15)
5 Stocks Set to Soar on Bullish Earnings
at The Street - Mon Mar 30, 6:56AM CDT
These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.
VTNR: 3.68 (+0.18), FRPT: 20.05 (+0.74), CONN: 28.67 (-1.12), CLDN: 21.67 (+0.58), SNX: 78.11 (+1.93)
1 Clinical-Stage Biotech Stock That Could Make You Into a Millionaire
George Budwell, The Motley Fool - Motley Fool - Sun Mar 29, 7:06AM CDT
Biotech stocks have the ability to absolutely crush it in short order, turning even small investments into respectable sums of money. Investors that caught lightning in a bottle with Acadia Pharmaceuticals prior to the company releasing pivotal...
BLUE: 123.89 (+9.48), ACAD: 33.35 (+1.39), CLDN: 21.67 (+0.58)
Next Week In Biotech: AcelRx's New CEO, RXi And Celladon Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 27, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
IMDZ: 22.77 (-1.32), ARGS: 9.52 (+0.35), RXII: 0.74 (-0.02), CTSO: 13.87 (-0.43), ADK: 4.25 (+0.02), RGDX: 0.44 (-0.01), CLDN: 21.67 (+0.58)
Celladon to Report Fourth Quarter and Fiscal 2014 Results on March 31
GlobeNewswire - Wed Mar 25, 3:04PM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that it will report its results for the fourth quarter and fiscal year ended December 31, 2014 on Tuesday, March 31, 2015. The company will issue a press release before the market opens and host a live investor conference call and webcast at 8:30am Eastern/5:30am Pacific.
CLDN: 21.67 (+0.58)
Celladon Heart-Failure Study Looms Large as Next Big Test for Gene Therapy
at The Street - Wed Mar 25, 9:06AM CDT
In April, Celladon is expecting results from a mid-stage study of a gene therapy aiming to improve the pumping ability of the heart in patients with advanced heart failure.
BLUE: 123.89 (+9.48), ONCE: 74.13 (+5.25), CLDN: 21.67 (+0.58)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 4:35PM CDT
RPTP: 12.04 (+0.07), CBK: 5.43 (-0.10), NSM: 24.76 (-0.26), ENOC: 11.08 (+0.15), TGS: 5.18 (-0.04), CLDN: 21.67 (+0.58), ARNA: 4.48 (+0.15), ENLK: 25.19 (-0.06), LXK: 43.13 (-0.17), KFX: 10.95 (+0.03)
Novasep and Celladon Execute MYDICAR API Supply Agreement
GlobeNewswire - Tue Mar 24, 3:05PM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage cardiovascular gene therapy company and Novasep, a leading supplier of services and technologies for the life sciences and chemical industries, today announce that they have signed a Development, Manufacturing and Supply Agreement pursuant to which, if supported by upcoming MYDICAR clinical data, Novasep would manufacture MYDICAR drug substance through 2018 with extension options through 2020.
CLDN: 21.67 (+0.58)
The Airline Triad - Cramer's Lightning Round (3/20/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Mar 23, 4:41AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, March 20. Bullish Calls: Celladon Corp (NASDAQ: CLDN ): "A pretty good spec. A lot of different compounds, and I am willing to go for it. I know it...
CNC: 71.23 (+2.01), WFM: 52.35 (+0.42), TTWO: 25.21 (-0.05), SAVE: 78.30 (+1.66), VA: 31.30 (+1.04), AAL: 53.64 (+0.98), DD: 72.58 (+0.93), CLDN: 21.67 (+0.58), SIRI: 3.87 (+0.02), LUV: 44.58 (+0.34), KING: 15.85 (+0.32)
'Mad Money' Lightning Round: Buy, Buy, Buy Whole Foods Markets
at The Street - Sat Mar 21, 5:00AM CDT
Cramer likes Celladon and Sirius XM Radio, thinks Centene is amazing and is avoiding King Digital and Virgin America.
WFM: 52.35 (+0.42), CNC: 71.23 (+2.01), TTWO: 25.21 (-0.05), SAVE: 78.30 (+1.66), VA: 31.30 (+1.04), ACHN: 10.24 (+0.08), DD: 72.58 (+0.93), CLDN: 21.67 (+0.58), AAL: 53.64 (+0.98), SIRI: 3.87 (+0.02), LUV: 44.58 (+0.34), KING: 15.85 (+0.32)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Mar 20, 7:24PM CDT
Cramer says it's time to take some profits and raise cash for the next speed bump. He'll be watching company earnings from Sonic, Paychex and GameStop, among others.
MKC: 78.02 (+0.69), NKE: 100.89 (+1.01), BBRY: 8.80 (-0.66), CLDN: 21.67 (+0.58), PVH: 105.36 (+1.45), LUV: 44.58 (+0.34), PAYX: 50.01 (+0.46), SAVE: 78.30 (+1.66), VA: 31.30 (+1.04), SONC: 32.29 (+0.23), DPZ: 102.55 (+1.50), DD: 72.58 (+0.93), AAL: 53.64 (+0.98), PRTA: 39.37 (+1.53), SIRI: 3.87 (+0.02), KING: 15.85 (+0.32), WFM: 52.35 (+0.42), GME: 37.69 (-0.67), GIII: 112.47 (+0.69), FIVE: 35.49 (+0.25), FINL: 24.74 (+1.12), LULU: 64.83 (+0.51), DRI: 69.42 (+0.37), CNC: 71.23 (+2.01), TTWO: 25.21 (-0.05), FRSH: 18.18 (+0.33), ACHN: 10.24 (+0.08)
Nasdaq stocks posting largest percentage increases
AP - Fri Mar 20, 12:25PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
BIIB: 431.62 (+1.75), GLMD: 9.73 (-0.30), HIIQ: 7.87 (-0.64), VTAE: 11.31 (+0.10), CLDN: 21.67 (+0.58), ATRA: 42.90 (+6.30), VBLT: 5.29 (-0.39), CORT: 5.62 (+0.04), FPRX: 23.76 (+1.23)
Celladon Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire - Mon Mar 16, 6:00AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that on March 9, 2015 the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 40,000 shares of common stock to three new employees, with two of such grants having a grant date of March 9, 2015 (the "March 9 Grants"
and the third having a grant date of March 11, 2015 (the "March 11 Grant", with each such grant date corresponding to the employees' respective hire dates.
CLDN: 21.67 (+0.58)
Could This Clinical-Stage Biotech Stock Soar in April?
George Budwell, The Motley Fool - Motley Fool - Thu Mar 12, 7:59AM CDT
Biotech stocks are known for their wild ways. Over the last few years, for instance, we have witnessed dozens of small-cap companies soar -- as well as sink -- following pivotal clinical or regulatory catalysts. Perhaps one of the most intriguing...
BLUE: 123.89 (+9.48), ICPT: 295.91 (+2.00), CLDN: 21.67 (+0.58)
Nasdaq stocks posting largest volume increases
AP - Fri Mar 06, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
ICEL: 16.42 (+8.48), GILT: 6.08 (+0.13), CLDN: 21.67 (+0.58), ITCI: 24.73 (-0.55), DRRX: 2.00 (+0.12), DRAD: 4.43 (-0.06)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 11:45AM CST
SSH: 4.16 (-0.02), ONCY: 0.77 (unch), LTM: 71.08 (+0.10), LEDS: 0.62 (-0.02), CLDN: 21.67 (+0.58), AXN: 1.70 (-0.12), EXAS: 23.03 (+0.54), DRRX: 2.00 (+0.12), DRAD: 4.43 (-0.06), BLRX: 2.16 (+0.01), GENE: 4.94 (+1.24), OREX: 7.75 (+0.21), ICEL: 16.42 (+8.48), BORN: 1.14 (+0.04), DMD: 5.88 (-0.11), AVEO: 1.44 (+0.07), CALA: 16.42 (-1.03), MTL: 1.35 (+0.12), CKP: 10.86 (+0.16), ERII: 2.59 (-0.05)
Celladon reports Q4 results
Seeking Alpha - at Seeking Alpha - 1 hr 10 mins ago
CLDN: 21.67 (+0.58)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:11AM CDT
BDSI: 10.51 (-3.38), CRMD: 8.70 (+0.56), NCFT: 25.67 (+2.77), LEJU: 8.47 (+0.56), CTRX: 59.83 (+11.51), ZIOP: 11.61 (+0.17), ADXS: 13.44 (+0.29), CNAT: 7.53 (-0.22), XON: 46.30 (+3.30), BBEP: 5.55 (-0.35), ADMP: 3.83 (-1.56), CLDN: 21.67 (+0.58), ASPX: 100.36 (+29.45), HPTX: 45.98 (+3.24), GENE: 4.94 (+1.24), SYN: 2.29 (-0.03), ICEL: 16.42 (+8.48), HZNP: 25.78 (+3.97), OHRP: 2.81 (+0.07), SFUN: 6.35 (+0.39), CNET: 1.66 (+0.15)
5 Stocks Set to Soar on Bullish Earnings
at The Street - Mon Mar 30, 6:56AM CDT
These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.
VTNR: 3.68 (+0.18), FRPT: 20.05 (+0.74), CONN: 28.67 (-1.12), CLDN: 21.67 (+0.58), SNX: 78.11 (+1.93)
1 Clinical-Stage Biotech Stock That Could Make You Into a Millionaire
George Budwell, The Motley Fool - Motley Fool - Sun Mar 29, 7:06AM CDT
Biotech stocks have the ability to absolutely crush it in short order, turning even small investments into respectable sums of money. Investors that caught lightning in a bottle with Acadia Pharmaceuticals prior to the company releasing pivotal...
BLUE: 123.89 (+9.48), ACAD: 33.35 (+1.39), CLDN: 21.67 (+0.58)
Next Week In Biotech: AcelRx's New CEO, RXi And Celladon Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 27, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
IMDZ: 22.77 (-1.32), ARGS: 9.52 (+0.35), RXII: 0.74 (-0.02), CTSO: 13.87 (-0.43), ADK: 4.25 (+0.02), RGDX: 0.44 (-0.01), CLDN: 21.67 (+0.58)
Celladon to Report Fourth Quarter and Fiscal 2014 Results on March 31
GlobeNewswire - Wed Mar 25, 3:04PM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that it will report its results for the fourth quarter and fiscal year ended December 31, 2014 on Tuesday, March 31, 2015. The company will issue a press release before the market opens and host a live investor conference call and webcast at 8:30am Eastern/5:30am Pacific.
CLDN: 21.67 (+0.58)
Celladon Heart-Failure Study Looms Large as Next Big Test for Gene Therapy
at The Street - Wed Mar 25, 9:06AM CDT
In April, Celladon is expecting results from a mid-stage study of a gene therapy aiming to improve the pumping ability of the heart in patients with advanced heart failure.
BLUE: 123.89 (+9.48), ONCE: 74.13 (+5.25), CLDN: 21.67 (+0.58)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 4:35PM CDT
RPTP: 12.04 (+0.07), CBK: 5.43 (-0.10), NSM: 24.76 (-0.26), ENOC: 11.08 (+0.15), TGS: 5.18 (-0.04), CLDN: 21.67 (+0.58), ARNA: 4.48 (+0.15), ENLK: 25.19 (-0.06), LXK: 43.13 (-0.17), KFX: 10.95 (+0.03)
Novasep and Celladon Execute MYDICAR API Supply Agreement
GlobeNewswire - Tue Mar 24, 3:05PM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage cardiovascular gene therapy company and Novasep, a leading supplier of services and technologies for the life sciences and chemical industries, today announce that they have signed a Development, Manufacturing and Supply Agreement pursuant to which, if supported by upcoming MYDICAR clinical data, Novasep would manufacture MYDICAR drug substance through 2018 with extension options through 2020.
CLDN: 21.67 (+0.58)
The Airline Triad - Cramer's Lightning Round (3/20/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Mar 23, 4:41AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, March 20. Bullish Calls: Celladon Corp (NASDAQ: CLDN ): "A pretty good spec. A lot of different compounds, and I am willing to go for it. I know it...
CNC: 71.23 (+2.01), WFM: 52.35 (+0.42), TTWO: 25.21 (-0.05), SAVE: 78.30 (+1.66), VA: 31.30 (+1.04), AAL: 53.64 (+0.98), DD: 72.58 (+0.93), CLDN: 21.67 (+0.58), SIRI: 3.87 (+0.02), LUV: 44.58 (+0.34), KING: 15.85 (+0.32)
'Mad Money' Lightning Round: Buy, Buy, Buy Whole Foods Markets
at The Street - Sat Mar 21, 5:00AM CDT
Cramer likes Celladon and Sirius XM Radio, thinks Centene is amazing and is avoiding King Digital and Virgin America.
WFM: 52.35 (+0.42), CNC: 71.23 (+2.01), TTWO: 25.21 (-0.05), SAVE: 78.30 (+1.66), VA: 31.30 (+1.04), ACHN: 10.24 (+0.08), DD: 72.58 (+0.93), CLDN: 21.67 (+0.58), AAL: 53.64 (+0.98), SIRI: 3.87 (+0.02), LUV: 44.58 (+0.34), KING: 15.85 (+0.32)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Mar 20, 7:24PM CDT
Cramer says it's time to take some profits and raise cash for the next speed bump. He'll be watching company earnings from Sonic, Paychex and GameStop, among others.
MKC: 78.02 (+0.69), NKE: 100.89 (+1.01), BBRY: 8.80 (-0.66), CLDN: 21.67 (+0.58), PVH: 105.36 (+1.45), LUV: 44.58 (+0.34), PAYX: 50.01 (+0.46), SAVE: 78.30 (+1.66), VA: 31.30 (+1.04), SONC: 32.29 (+0.23), DPZ: 102.55 (+1.50), DD: 72.58 (+0.93), AAL: 53.64 (+0.98), PRTA: 39.37 (+1.53), SIRI: 3.87 (+0.02), KING: 15.85 (+0.32), WFM: 52.35 (+0.42), GME: 37.69 (-0.67), GIII: 112.47 (+0.69), FIVE: 35.49 (+0.25), FINL: 24.74 (+1.12), LULU: 64.83 (+0.51), DRI: 69.42 (+0.37), CNC: 71.23 (+2.01), TTWO: 25.21 (-0.05), FRSH: 18.18 (+0.33), ACHN: 10.24 (+0.08)
Nasdaq stocks posting largest percentage increases
AP - Fri Mar 20, 12:25PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
BIIB: 431.62 (+1.75), GLMD: 9.73 (-0.30), HIIQ: 7.87 (-0.64), VTAE: 11.31 (+0.10), CLDN: 21.67 (+0.58), ATRA: 42.90 (+6.30), VBLT: 5.29 (-0.39), CORT: 5.62 (+0.04), FPRX: 23.76 (+1.23)
Celladon Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire - Mon Mar 16, 6:00AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that on March 9, 2015 the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 40,000 shares of common stock to three new employees, with two of such grants having a grant date of March 9, 2015 (the "March 9 Grants"
and the third having a grant date of March 11, 2015 (the "March 11 Grant", with each such grant date corresponding to the employees' respective hire dates. CLDN: 21.67 (+0.58)
Could This Clinical-Stage Biotech Stock Soar in April?
George Budwell, The Motley Fool - Motley Fool - Thu Mar 12, 7:59AM CDT
Biotech stocks are known for their wild ways. Over the last few years, for instance, we have witnessed dozens of small-cap companies soar -- as well as sink -- following pivotal clinical or regulatory catalysts. Perhaps one of the most intriguing...
BLUE: 123.89 (+9.48), ICPT: 295.91 (+2.00), CLDN: 21.67 (+0.58)
Nasdaq stocks posting largest volume increases
AP - Fri Mar 06, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
ICEL: 16.42 (+8.48), GILT: 6.08 (+0.13), CLDN: 21.67 (+0.58), ITCI: 24.73 (-0.55), DRRX: 2.00 (+0.12), DRAD: 4.43 (-0.06)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 11:45AM CST
SSH: 4.16 (-0.02), ONCY: 0.77 (unch), LTM: 71.08 (+0.10), LEDS: 0.62 (-0.02), CLDN: 21.67 (+0.58), AXN: 1.70 (-0.12), EXAS: 23.03 (+0.54), DRRX: 2.00 (+0.12), DRAD: 4.43 (-0.06), BLRX: 2.16 (+0.01), GENE: 4.94 (+1.24), OREX: 7.75 (+0.21), ICEL: 16.42 (+8.48), BORN: 1.14 (+0.04), DMD: 5.88 (-0.11), AVEO: 1.44 (+0.07), CALA: 16.42 (-1.03), MTL: 1.35 (+0.12), CKP: 10.86 (+0.16), ERII: 2.59 (-0.05)
